Orgenesis Financial Statements From 2010 to 2025
| ORGS Stock | USD 0.15 0.13 46.43% |
Check Orgenesis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Orgenesis' main balance sheet or income statement drivers, such as , as well as many indicators such as . Orgenesis financial statements analysis is a perfect complement when working with Orgenesis Valuation or Volatility modules.
Orgenesis |
Orgenesis Company Return On Equity Analysis
Orgenesis' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Orgenesis Return On Equity | -7.27 |
Most of Orgenesis' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Orgenesis is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Orgenesis has a Return On Equity of -7.2725. This is 69.66% lower than that of the Biotechnology sector and 80.05% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Orgenesis Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Orgenesis's current stock value. Our valuation model uses many indicators to compare Orgenesis value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Orgenesis competition to find correlations between indicators driving Orgenesis's intrinsic value. More Info.Orgenesis is regarded third in return on equity category among its peers. It is regarded fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Orgenesis' earnings, one of the primary drivers of an investment's value.About Orgenesis Financial Statements
Orgenesis shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Orgenesis investors may analyze each financial statement separately, they are all interrelated. The changes in Orgenesis' assets and liabilities, for example, are also reflected in the revenues and expenses on on Orgenesis' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 151 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Orgenesis Pink Sheet Analysis
When running Orgenesis' price analysis, check to measure Orgenesis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orgenesis is operating at the current time. Most of Orgenesis' value examination focuses on studying past and present price action to predict the probability of Orgenesis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orgenesis' price. Additionally, you may evaluate how the addition of Orgenesis to your portfolios can decrease your overall portfolio volatility.